Digital Therapeutics Market Size, Share and Trends 2025 to 2034

Digital Therapeutics Market Size and Forecast 2025 to 2034

The global digital therapeutics market size was estimated at USD 7.88 billion in 2024 and is predicted to increase from USD 9.73 billion in 2025 to approximately USD 56.76 billion by 2034, expanding at a CAGR of 21.65% from 2025 to 2034.

Digital Therapeutics Market Key Takeaways

• North America contributed the largest market share of 43.91% in 2024.
• By product type, the prescription digital therapeutics (PDTs) segment dominated the market with 29.40% market share in 2024. The dominance of the segment can be attributed to the rising incidence of chronic diseases.
• By product type, the behavioural & cognitive interventions via digital platforms segment are expected to grow at the highest CAGR of 10.20% in 2024. The dominance of the segment can be credited to the rise in the adoption of smartphones.
• By therapy area, the central nervous system (CNS) / neuroscience segment led the market by holding 32.60% market share in 2024. The dominance of the segment can be linked to the surge in incidence of mental and neurological health disorders.
• By therapy area, the metabolic and endocrine segment is expected to grow at the highest CAGR of 10.80% in 2024. The dominance of the segment can be driven by the rising incidence of diabetes, obesity, and metabolic syndrome.
• By delivery platform, the mobile applications (iOS, Android) segment held a 40.70% market share in 2024. The dominance of the segment is owed to the growing adoption of smartphones and tablets, and innovations in network infrastructure and coverage.
• By delivery platform, the AI-based chatbots or coaching interfaces segment is expected to grow at the highest CAGR of 11.10% in 2024. The dominance of the segment is due to the rising incidence of chronic diseases.
• By business model, the B2B2C segment dominated the market with a 35.80% share in 2024. Digital therapeutics are particularly effective in managing chronic diseases such as diabetes, hypertension, and mental health disorders.
• By business model, the reimbursement-based segment is expected to grow at the highest CAGR of 10.40% in 2024. The dominance of the segment can be attributed to the rising incidence of chronic diseases.
• By end user, the patients segment dominated the market with 47.30% market share in 2024. The dominance of the segment can be credited to the rising incidence of chronic diseases and the global surge in the geriatric population.
• By end user, the payers segment is expected to grow at the fastest CAGR of 9.60% in 2024. The dominance of the segment can be linked to its important role in the adoption of Digital Therapeutics (DTx).

U.S. Digital Therapeutics Market Size and Growth 2025 to 2034

The U.S. digital therapeutics market size was estimated at USD 3.02 billion in 2024 and is predicted to be worth around USD 20.98 billion by 2034, registering a solid CAGR of 21.38% between 2024 and 2034.

North America emerged as a global leader in the global digital therapeutics market with a revenue share of 43.91% in 2023 owing to the increasing number of reforms pertaining to curtail the rising healthcare spending across the region. Furthermore, the region is a hub for a large number of solutions providers for digital therapeutics that again drive the market growth in the region.

The digital therapeutics market expansion in this region is fueled by factors such as the entry of new startups, changes in the reimbursement structure of digital therapeutics, increased investments in digital therapeutics, and growing government initiatives to assist technological developments.

Apart from this, the Asia Pacific is expected to witness the fastest growth over the analysis period because of a large consumer base along with a rising geriatric population in the region. Due to its early acceptance of new and innovative technology and increased investment through funding, the Asia-Pacific is likely to dominate the market. The investment is related to increased government investment, mergers, and acquisitions.

Digital Therapeutics Market Trends

• The incorporation of AI and wearable devices enhances the personalization and effectiveness of digital therapeutics solutions.
• Regulatory advancement and reimbursement models are paving the way for broader adoption.
• Shift towards value-based care models, emphasizing patient outcomes and cost effectiveness.
• Increasing patient engagement and accessibility fur to user-friendly and interactive features.

Digital Therapeutics Market Growth Factors

The patients can receive evidence-based treatment interventions using digital therapies. It is used to manage, prevent, or treat medical conditions using software applications and equipment. To provide patient care and health results, the digital therapeutics software can be used alone or in conjunction with other therapies.

The rising frequency of preventable chronic disorders such as cancer and diabetes, the need to control healthcare costs, increased investments in digital medicines, and a growing focus on preventive healthcare are all driving the growth of the digital therapeutics market.

One of the key factors driving the growth of digital therapeutics market is the rising focus on preventative healthcare by governments around the world. The governments are taking steps and implementing programs to increase the rate of use of these devices, which is a shift from the traditional healthcare methods.

Increasing penetration of digital healthcare applications & platforms because of rapid adoption of smartphones & tablets expected to spur the market growth over the upcoming years.

Rising prevalence of chronic diseases coupled with increasing need to regulate the escalating cost of healthcare facilities is likely to impel the market growth. Further, constantly changing digital platforms in various sectors has grappled consumers towards using of these digital platforms as well as increasing awareness pertaining to health and fitness are the primary factors that boost the market growth over the forthcoming timeframe.

Although digital therapeutics witnesses significant development and numerous advancements, it is still at a niche phase and the application developers face lot of difficulty due to lack of proper monetization strategy. Presently, advertisements along with the paid content are the prime source of revenue generation, yet are insufficient to meet the financial requirements. The aforementioned factors are anticipated to adversely affect the market growth.

Market Scope

Market Dynamics

Drivers

Growing geriatric population

The growing geriatric population globally is one of the primary factors driving up demand for digital therapeutics. The global population of people aged 60 and up is expected to reach 2.1 billion by 2050, according to the United Nations. People over the age of 60 are more susceptible to illnesses such as obesity, cancer, and diabetes, increasing the demand for digital therapeutics. Thus, during the forecast period, the growing geriatric population is driving the growth of the digital therapeutics market.

Restraints

Data privacy concerns

The various health applications lack necessary authorization in several countries, raising issues about the product and data quality, patient privacy, security, and data use responsibly. The patient’s information is accessible by digital therapeutics providers, but they are not allowed to share it with anybody who is not involved in the patient’s treatment. However, with the use of digital technologies to integrate data, the patient’s information is at risk of being accessible by any healthcare professional who is not involved in the patient’s treatment program. Thus, the data privacy concerns is hindering the growth of digital therapeutics market during the forecast period.

Opportunities

Rising prevalence of chronic diseases

The chronic disease’s high prevalence is a key source of concern for healthcare systems all over the world. The treatment of chronic disorders patients is difficult due to psychological variables influencing the patients. The patients must adapt their behavior as a part of new self-care lifestyle because chronic diseases are generally linked with a high level of unpredictability. Moreover, many chronic diseases and ailments progress with the time, and their prevalence increases as people get older. As a result, chronic problems are likely to increase even more in the coming years as the global senior population continues to grow. As a result, the rising prevalence of chronic diseases is creating lucrative opportunities for the growth of digital therapeutics during the forecast period.

Challenges

Lack of consumer awareness

Motivating people to use digital therapeutics and gaining their trust is a major challenge for providers of digital therapeutics. The old age people are more vulnerable to the chronic disorders. Furthermore, the extent to which behavioral change can be observed with digital therapeutics remains unknown.

Product Insights

The prescription digital therapeutics (PDTs) segment dominated the market with 29.40% market share in 2024. The dominance of the segment can be attributed to the rising incidence of chronic diseases, along with ongoing innovations in technology, with the increasing focus on personalized and preventative care.PDTs can minimize the need for hospitalizations, frequent doctor visits, and expensive medications.

The behavioural & cognitive interventions via digital platforms segment is expected to grow at the highest CAGR of 10.20% in 2024. The dominance of the segment can be credited to the rise in adoption of smartphones and the enhanced network infrastructure. Also, these platforms provide clinically validated solutions for safeguarding, managing, and treating various conditions like mental health disorders.

Therapy Area Insights

The central nervous system (CNS) / neuroscience segment led the market by holding 32.60% market share in 2024. The dominance of the segment can be linked to the surge in incidence of mental and neurological health disorders and the rising adoption of digital health solutions with innovations in AI and machine learning. Moreover, the increasing emphasis on preventative healthcare, especially for lifestyle-related conditions, can further positively impact segment growth.

The metabolic and endocrine segment is expected to grow at the highest CAGR of 10.80% in 2024. The dominance of the segment can be driven by the rising incidence of diabetes, obesity, and metabolic syndrome, coupled with the increasing adoption of patient-oriented care. The growth is also boosted by innovations in technology, including artificial intelligence and machine learning.

Delivery Platform Insights

The mobile applications (iOS, Android) segment held a 40.70% market share in 2024. The dominance of the segment is owed to the growing adoption of smartphones and tablets, and innovations in network infrastructure and coverage. In addition, the raised regulatory support and the development of reimbursement models for digital therapeutics are also impacting segment growth.

The AI-based chatbots or coaching interfaces segment is expected to grow at the highest CAGR of 11.10% in 2024. The dominance of the segment is due to the rising incidence of chronic diseases and the increasing adoption of mobile internet and smartphones. Furthermore, digital solutions can be more cost-effective than conventional healthcare, which makes them a more accessible solution for individuals and healthcare systems.

Business Model Insights

The B2B2C segment dominated the market with a 35.80% share in 2024. Digital therapeutics are particularly effective in managing chronic diseases such as diabetes, hypertension, and mental health disorders. B2B customers, such as healthcare providers and employers, face significant costs related to these conditions and thus have a strong incentive to adopt digital therapeutics to manage them more efficiently.

Digital therapeutics offer robust data analytics capabilities, providing healthcare providers and employers with actionable insights into patient or employee health trends. This data can be used to personalize treatments, improve health outcomes, and demonstrate the value of these solutions. These solutions are designed to integrate with existing healthcare IT systems, such as EHRs and health information exchanges (HIEs), facilitating seamless data flow and enhancing the overall care delivery process.

The reimbursement-based segment is expected to grow at the highest CAGR of 10.40% in 2024. The dominance of the segment can be attributed to the rising incidence of chronic diseases and the ability of DTx to provide cost-effective and accessible care. Moreover, the shift towards value-based care models, which incentivize suppliers for enhanced patient outcomes, is creating a reliable environment for DTx adoption, impacting positive segment growth further.

End User Insights

The patients segment dominated the market with a 47.30% market share in 2024. The dominance of the segment can be credited to the rising incidence of chronic diseases, global surge in the geriatric population, and increasing demand for accessible and affordable healthcare solutions. Also, innovations in technology and the ongoing transition towards patient-centric care are contributing to the expansion of segments further.

The payers segment is expected to grow at the fastest CAGR of 9.60% in 2024. The dominance of the segment can be linked to its important role in the adoption of Digital Therapeutics (DTx), with the increasing recognition of DTx's value. In addition, payers are rapidly seeking new solutions to mitigate rising costs associated with healthcare, especially for chronic diseases, driving segment growth soon.

Digital Therapeutics Market Companies

• Fitbit Health Solutions
• 2MORROW, Inc.
• Medtronic Plc.
• Livongo Health, Inc.
• Pear Therapeutics, Inc.
• Omada Health, Inc.
• Resmed, Inc. (Propeller Health)
• Proteus Digital Health, Inc.
• Welldoc, Inc.
• Voluntis, Inc.
• Canary Health Inc.
• Noom, Inc.
• Mango Health Inc.
• Dthera Sciences

Segments Covered in the Report

By Product Type

• Prescription Digital Therapeutics (PDTs)
• Non-prescription DTx (Wellness-validated DTx)
• Digital Companions (for Rx drugs)
• Remote Monitoring Tools / Digital Biomarkers
• Behavioral & Cognitive Interventions via Digital Platforms
• Mobile Health (mHealth) Applications
• Virtual Coaching & Adherence Tools

By Therapy Area

• Central Nervous System (CNS) / Neuroscience
  
  • Depression
  • Anxiety
  • ADHD
  • Schizophrenia
  • Insomnia
  • Cognitive impairment (e.g., Alzheimer’s, MCI)
• Gastrointestinal Disorders (GI)
  
  • IBS (Irritable Bowel Syndrome)
  • IBD (Crohn’s, Ulcerative Colitis)
  • Functional GI disorders
  • Post-operative GI management
• Metabolic and Endocrine
  
  • Type 1 & Type 2 Diabetes
  • Obesity
  • Metabolic syndrome
• Oncology (Supportive care DTx)
  
  • Pain management
  • Chemotherapy-induced nausea
  • Psychological support (anxiety, depression)
  • Fatigue and sleep disturbances
• Rare Diseases (Support & Monitoring)
  
  • DTx applications for remote management, patient engagement, and symptom monitoring in rare genetic/metabolic conditions
• Other Areas
  
  • Cardiovascular health (hypertension, post-MI recovery)
  • Respiratory (asthma, COPD)
  • Addiction (alcohol, opioids, nicotine)
  • Women’s health (fertility, pregnancy monitoring)

By Delivery Platform

• Mobile Applications (iOS, Android)
• Web-based Platforms / Portals
• Smart Wearables
• VR/AR-based Interventions
• Connected Medical Devices (e.g., digital inhalers, glucose monitors)
• AI-based Chatbots or Coaching Interfaces

By Business Model

• B2B2C
• Direct-to-Consumer (D2C)
• Pharma-DTx Partnerships (Companion DTx or Co-commercialization)
• Reimbursement-based (Formulary inclusion, CMS approvals)
• Employer Health Programs

By End User

• Patients
• Healthcare Providers
• Payers
• Pharmaceutical Companies

By Regional Outlook

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • France
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
• Latin America
• MEA